Daniel Pichl Spring Works Therapeutics, Inc. (SWTX) insider trading activity

Daniel Pichl is Chief People Officer of SpringWorks Therapeutics, Inc.. Currently has a direct ownership of 50,762 shares of SWTX, which is worth approximately $2.96 Million. The most recent transaction as insider was on Feb 10, 2025, when has been sold 29,750 shares (Common Stock) at a price of $54.81 per share, resulting in proceeds of $1,630,597. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50.8K

12.28% 3M change

12.28% 12M change

Total Value Held $2.96 Million

Daniel Pichl Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 10 2025	SELL Open market or private sale	$1,630,597 $54.81 p/Share	29,750 Reduced 36.95%	50,762 Common Stock
Feb 10 2025	BUY Exercise of conversion of derivative security	$822,290 $27.64 p/Share	29,750 Added 26.98%	80,512 Common Stock
Jan 10 2025	BUY Grant, award, or other acquisition	-	12,819 Added 20.16%	50,762 Common Stock
Jan 06 2025	SELL Payment of exercise price or tax liability	$68,354 $38.86 p/Share	1,759 Reduced 4.43%	37,943 Common Stock
Jan 05 2025	SELL Payment of exercise price or tax liability	$96,315 $38.19 p/Share	2,522 Reduced 5.97%	39,702 Common Stock
Jan 04 2025	SELL Payment of exercise price or tax liability	$114,111 $38.19 p/Share	2,988 Reduced 6.61%	42,224 Common Stock
Feb 16 2024	SELL Open market or private sale	$751,500 $50.1 p/Share	15,000 Reduced 24.91%	45,212 Common Stock
Feb 16 2024	BUY Exercise of conversion of derivative security	$414,600 $27.64 p/Share	15,000 Added 19.94%	60,212 Common Stock
Feb 02 2024	SELL Open market or private sale	$1,181,548 $45.13 p/Share	26,181 Reduced 36.67%	45,212 Common Stock
Feb 02 2024	BUY Exercise of conversion of derivative security	$449,150 $27.64 p/Share	16,250 Added 18.54%	71,393 Common Stock
Jan 08 2024	SELL Payment of exercise price or tax liability	$58,349 $41.53 p/Share	1,405 Reduced 2.48%	55,143 Common Stock
Jan 05 2024	SELL Payment of exercise price or tax liability	$59,749 $37.96 p/Share	1,574 Reduced 2.71%	56,548 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	22,919 Added 28.28%	58,122 Common Stock
Jan 26 2023	SELL Open market or private sale	$26,598 $31.0 p/Share	858 Reduced 2.38%	35,203 Common Stock
Jan 07 2023	SELL Payment of exercise price or tax liability	$14,419 $26.41 p/Share	546 Reduced 1.49%	36,061 Common Stock
Jan 06 2023	SELL Payment of exercise price or tax liability	$47,306 $27.52 p/Share	1,719 Reduced 4.49%	36,607 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	19,425 Added 33.64%	38,326 Common Stock
Jan 07 2022	SELL Payment of exercise price or tax liability	$47,203 $56.06 p/Share	842 Reduced 3.78%	21,456 Common Stock
Jan 06 2022	BUY Grant, award, or other acquisition	-	13,062 Added 36.94%	22,298 Common Stock
Sep 08 2021	BUY Exercise of conversion of derivative security	$99,992 $43.1 p/Share	2,320 Added 20.08%	9,236 Common Stock
Jan 07 2021	BUY Grant, award, or other acquisition	-	4,150 Added 50.0%	4,150 Common Stock

Daniel Pichl

Chief People Officer

Stamford, CT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SWTX shares.

Notify only if

Value

Insider Trading

Get notified when an Spring Works Therapeutics, Inc. insider buys or sells SWTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to SpringWorks Therapeutics, Inc.

Track Activities on SWTX

Account